What does DEVANTHINIC PHARMA do?

DEVANTHINIC PHARMA is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 16 December 2014, 1 establishment.

What is the address of DEVANTHINIC PHARMA?

The registered office of DEVANTHINIC PHARMA is located at Rue des Canadiens 24, 7180 Seneffe.

Is DEVANTHINIC PHARMA still active?

Yes. According to the CBE (29 October 2026) DEVANTHINIC PHARMA is active, legal situation “Normale toestand”, started on 16 December 2014.

Is DEVANTHINIC PHARMA registered on Peppol?

Yes, DEVANTHINIC PHARMA is registered on the Peppol network with ID 0208:0506893294.

What is the enterprise number of DEVANTHINIC PHARMA?

The enterprise number of DEVANTHINIC PHARMA is BE0506893294.

When was DEVANTHINIC PHARMA founded?

DEVANTHINIC PHARMA was founded on 16 December 2014.

Who are the directors of DEVANTHINIC PHARMA?

According to the 2025 annual accounts, the directors of DEVANTHINIC PHARMA are: Anne André.

Is DEVANTHINIC PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 December 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DEVANTHINIC PHARMA make in 2025?

DEVANTHINIC PHARMA posted a profit after taxes of € 888,590 in financial year 2025.

What is the revenue of DEVANTHINIC PHARMA?

As a small company, DEVANTHINIC PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,319,368.

How much does an employee at DEVANTHINIC PHARMA earn?

The average wage cost per full-time employee at DEVANTHINIC PHARMA was € 51,400 in 2025: staff costs of € 431,503 for 8.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does DEVANTHINIC PHARMA have?

According to the 2025 annual accounts, DEVANTHINIC PHARMA has 8.4 full-time equivalents (FTE).

DEVANTHINIC PHARMA (Private Limited) - Seneffe

Dossier DEVANTHINIC PHARMA, printed on 29 October 2026 from databakkes.be/en/0506893294/devanthinic-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

11 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

DEVANTHINIC PHARMA from Seneffe, company number BE0506893294, closed financial year 2025 with a result of € 888,590 after tax. For that financial year DEVANTHINIC PHARMA recorded a gross margin of € 1.3 million and equity of € 7.7 million. Compared with financial year 2024, the result moved from € 983,178 to € 888,590. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Growing

€ 7.7 million

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 888,590

▼ 10% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 351,359

▼ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 7.6 million.

People and assets in 2025

Full-time equivalents

8.4

▲ 1.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 431,503

▲ 18% vs 2024

€ 51,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 34,185

▲ € 30,407 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 6.9 million

▼ 14% vs 2024

€ 594,027 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 171,972

▲ 73% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 72,526

▼ 34% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,208,169 Gross margin 2022: € 1,208,169 First fiscal year in the series	€ 1,232,569 Gross margin 2023: € 1,232,569 ▲ 2% vs 2022 (€ 1,208,169) Favourable step	€ 1,396,786 Gross margin 2024: € 1,396,786 ▲ 13% vs 2023 (€ 1,232,569) Favourable step	€ 1,319,368 Gross margin 2025: € 1,319,368 ▼ 6% vs 2024 (€ 1,396,786) Unfavourable step	▼ 6%
Profit after taxes	€ 1,755,903 Profit after taxes 2022: € 1,755,903 First fiscal year in the series	€ 641,951 Profit after taxes 2023: € 641,951 ▼ 63% vs 2022 (€ 1,755,903) Unfavourable step	€ 983,178 Profit after taxes 2024: € 983,178 ▲ 53% vs 2023 (€ 641,951) Favourable step	€ 888,590 Profit after taxes 2025: € 888,590 ▼ 10% vs 2024 (€ 983,178) Unfavourable step	▼ 10%
Equity	€ 5,220,235 Equity 2022: € 5,220,235 First fiscal year in the series	€ 5,862,185 Equity 2023: € 5,862,185 ▲ 12% vs 2022 (€ 5,220,235) Favourable step	€ 6,845,363 Equity 2024: € 6,845,363 ▲ 17% vs 2023 (€ 5,862,185) Favourable step	€ 7,733,953 Equity 2025: € 7,733,953 ▲ 13% vs 2024 (€ 6,845,363) Favourable step	▲ 13%
Total debts	€ 9,178,986 Total debts 2022: € 9,178,986 First fiscal year in the series	€ 9,754,528 Total debts 2023: € 9,754,528 ▲ 6% vs 2022 (€ 9,178,986) Unfavourable step	€ 9,632,939 Total debts 2024: € 9,632,939 ▼ 1% vs 2023 (€ 9,754,528) Favourable step	€ 8,693,728 Total debts 2025: € 8,693,728 ▼ 10% vs 2024 (€ 9,632,939) Favourable step	▼ 10%
Cash	€ 401,330 Cash 2022: € 401,330 First fiscal year in the series	€ 213,315 Cash 2023: € 213,315 ▼ 47% vs 2022 (€ 401,330) Unfavourable step	€ 462,442 Cash 2024: € 462,442 ▲ 117% vs 2023 (€ 213,315) Favourable step	€ 351,359 Cash 2025: € 351,359 ▼ 24% vs 2024 (€ 462,442) Unfavourable step	▼ 24%
Retained profit	€ 5,070,235 Retained profit 2022: € 5,070,235 First fiscal year in the series	€ 5,712,185 Retained profit 2023: € 5,712,185 ▲ 13% vs 2022 (€ 5,070,235) Favourable step	€ 6,695,363 Retained profit 2024: € 6,695,363 ▲ 17% vs 2023 (€ 5,712,185) Favourable step	€ 7,583,953 Retained profit 2025: € 7,583,953 ▲ 13% vs 2024 (€ 6,695,363) Favourable step	▲ 13%
Bank debt	€ 8,206,000 Bank debt 2022: € 8,206,000 First fiscal year in the series	€ 8,521,835 Bank debt 2023: € 8,521,835 ▲ 4% vs 2022 (€ 8,206,000) Unfavourable step	€ 8,104,315 Bank debt 2024: € 8,104,315 ▼ 5% vs 2023 (€ 8,521,835) Favourable step	€ 6,943,815 Bank debt 2025: € 6,943,815 ▼ 14% vs 2024 (€ 8,104,315) Favourable step	▼ 14%
Balance sheet total	€ 14,399,221 Balance sheet total 2022: € 14,399,221 First fiscal year in the series	€ 15,616,713 Balance sheet total 2023: € 15,616,713 ▲ 8% vs 2022 (€ 14,399,221) Unchanged	€ 16,687,393 Balance sheet total 2024: € 16,687,393 ▲ 7% vs 2023 (€ 15,616,713) Unchanged	€ 16,817,790 Balance sheet total 2025: € 16,817,790 ▲ 1% vs 2024 (€ 16,687,393) Unchanged	▲ 1%
Employees (FTE)	4.9 Employees (FTE) 2022: 4.9 First fiscal year in the series	6 Employees (FTE) 2023: 6 ▲ 1.1 vs 2022 (4.9) Unchanged	6.7 Employees (FTE) 2024: 6.7 ▲ 0.7 vs 2023 (6) Unchanged	8.4 Employees (FTE) 2025: 8.4 ▲ 1.7 vs 2024 (6.7) Unchanged	▲ 1.7

Key figures of DEVANTHINIC PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DEVANTHINIC PHARMA?

What happened at DEVANTHINIC PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: profit of € 888,590 (▼ 10% vs 2024). filed late Source: NBB ↗
Dec 18, 2014 New establishment in Seneffe. KBO
2014 Anne André became a director. NBB
Dec 16, 2014 Start of the company according to the CBE. KBO

In short

From € 1.8 million profit in 2022 to € 888,590 profit in 2025.

Paid € 725,797 in corporate taxes since 2022.

Best year ever: 2022, with € 1.8 million profit.

On average € 157,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Anne André

DEVANTHINIC PHARMA

PHARMACIE DE SENEFFE CENTRE 100%

PHARMACIE DE LA GRAND RUE 100%

PHARMACIE BASCOUP 100%

PHARMACIE LOISEAU 100%

Behind DEVANTHINIC PHARMA is Anne André. It owns 100% of PHARMACIE DE SENEFFE CENTRE, 100% of PHARMACIE DE LA GRAND RUE, 100% of PHARMACIE BASCOUP, 100% of PHARMACIE LOISEAU, 100% of PHARMACIE DE BESONRIEUX CENTRE and 100% of PHARMA-LOUVE itself.

Directors

According to the 2025 annual accounts

Anne André

Director

Also active at: PHARMACIE DE BASCOUP, Pharmacie LOISEAU, PHARMACIE DE LA GRAND RUE, PHARMACIE DE LA VILLE BASSE, PHARMA-LOUVE

since 2014

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Canadiens 24

7180 Seneffe

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.

All companies at this address →

PHARMACIE DE LA DRÊVE same network

€ 287,815 gross margin · 2025

PHARMACIE DE BOIS-D'HAINE same network

€ 317,344 gross margin · 2025

PHARMACIE DE BASCOUP same network

€ 517,152 gross margin · 2025

PHARMACIE SENEFFE CENTRE same network

€ 576,922 gross margin · 2025

PHARMACIE ANNE ANDRE same network

€ 357,760 gross margin · 2025

+6 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0506.893.294

VAT number

BE 0506.893.294

Registered office

Rue des Canadiens 24, 7180 Seneffe

Names & denominations

DEVANTHINIC PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 December 2014

Peppol

Active · Active since 29 Dec 2025

Activities · NACE

Activiteiten van holdings

Overige zakelijke dienstverlening, neg

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

DEVANTHINIC PHARMA

Warning lights

Financials

What happened to DEVANTHINIC PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions